Evidence gap analysis
Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation
Recent news and posts
New version of NABM nomenclature released
On October 9, 2024, the new version of the Nomenclature of Medical Biology Procedures (NABM 93) was released in France. Five new codes were introduced.
Some examples are provided below:
- 4510 "EGFR gene mutation detection test in non-small cell lung cancer for targeted therapy [Companion test]” (coefficient B - 950);
- 4511 “KRAS and NRAS gene mutation detection test in colorectal cancers for targeted therapy [Companion test]” (coefficient B - 1475).
Other changes included modification of the wording for several codes.
See the details in French here (NABM) and here (Decision on companion Dx codes).
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.